SCHEMBL20061333

SCHEMBL20061333

Cc1cc2cc(F)ccc2nc1C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
BACE1 P56817 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
CASP3 P42574 1/20 0.36
PDE10A Q9Y233 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MBNL1 Q9NR56 1/20 0.35
TYMS P04818 1/20 0.35
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
CYP1A1 P04798 1/20 0.34
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18819878 0.79 CYP1A2 (0.47) PDE3BPDE3ACYP1A2CYP3A4CYP2D6
SCHEMBL14911960 0.77 TDP1 (0.53) TSHRBACE1CYP1A2CYP2C19PDE10A
SCHEMBL2023290 0.76 KDM4E (0.44) TSHRCYP1A2CYP3A4CYP2C19CASP3
SCHEMBL2052776 0.76 KDM4E (0.44) TSHRCYP1A2CYP3A4CYP2C19CASP3
SCHEMBL12827021 0.76 TSHR (0.51) TSHRBACE1PDE3BPDE3ANPY1R
SCHEMBL16620893 0.76 TDP1 (0.50) TSHRCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL9251597 0.73 BACE1 (0.44) TSHRBACE1PDE3BPDE3ACYP1A2
SCHEMBL27746521 0.73 TDP1 (0.58) TSHRBACE1PDE3BPDE3ACYP1A2
SCHEMBL20061332 0.71 TSHR (0.32) TSHRBACE1PDE3BPDE3A
SCHEMBL20067902 0.71 SMN1; SMN2 (0.48) PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105527-A1 HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105527-A1 HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT WEE2, WEE1, ITK TSHR 4274/4885BACE1 2870/4885PDE3B 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.